Clinical trial · Observational
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
NEXTAR - NEXavar® as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma
NCT01508364CI-TRIAL-00016656NEXTARcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sorafenib (Nexavar, BAY 43-9006) | Drug | Sorafenib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- interventionNames
- Drug: Sorafenib (Nexavar, BAY 43-9006)
Primary outcomes (1)
- measure
- Duration of Nexavar treatment
- timeFrame
- up to 3 years
Secondary outcomes (5)
- measure
- Overall Survival (OS)
- timeFrame
- 1 - 1.5 years after LPLV
- measure
- Health related quality of life (HRQoL)
- timeFrame
- up to 3 years
- measure
- Progression-free survival (PFS)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar. * Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment. Exclusion Criteria: * Prior targeted therapy for RCC * Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).
References
Publications (0)
Data not yet available
No reference posted for this study.